Global Urokinase Powder market size is predicted to grow from US$ 73.08 million in 2025 to US$ 111 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.

Global Urokinase Powder Market Size, Share and Analysis 2026-32

The global Urokinase Powder market size is predicted to grow from US$ 73.08 million in 2025 to US$ 111 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032. Urokinase is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the bodys own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the mesh that holds a blood clot together. This is why urokinase is called a thrombolytic or clot-buster. The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings. A practical market definition should also include how urokinase is made, because that affects supply, regulatory burden, and cost. Urokinase products can differ by source. The U.S. Kinlytic label describes production from human neonatal kidney cells grown in tissue culture, and it explains extensive donor screening and virus testing/inactivation steps because it is derived from human source material. In contrast, some European product information describes urokinase that is extracted from human urine. These differences matter commercially: biologic sourcing and validation requirements make it harder for many manufacturers to enter, and they increase the importance of quality systems, change control, and reliable supply chains. On the demand side, the most basic driver is that blood clots are common, and a subset of them are severe enough that rapid clot removal is lifesaving or limb-saving. The U.S. CDC says up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, and VTE is linked to tens of thousands of deaths. Globally, cardiovascular diseases are still the leading cause of death, and they overlap with clot problems and high-risk hospital populations. These facts do not mean every clot patient needs urokinase. Most patients receive anticoagulants and supportive care, not thrombolytics. But they explain why hospitals continue to need a set of clot-management tools, including thrombolytic drugs, for the most urgent cases. In 2025, global Urokinase Powder production reached approximately 2490 BIU, with an average global market price of around US$ 30 per MIU. The global single-line production capacity ranges from 100 to 150 BIU per year. The industrys gross profit margin is approximately 25%-35%. One of the clearest growth pockets for urokinase is catheter and access-device management. Modern medicine uses a large volume of central venous catheters for chemotherapy, nutrition, antibiotics, and dialysis. These devices can become blocked by thrombus or fibrin sheaths. In Europe, regulatory summaries describe urokinase use for clots in catheters or cannulae, which is essentially catheter clearance. Clinical literature on thrombolytic therapy for catheter occlusion discusses multiple agents and reports that thrombolytics can restore patency in a meaningful share of blocked catheters, with performance differences by drug and dosing strategy; this is a major reason hospitals keep thrombolytic protocols for catheter salvage. When catheter salvage works, it avoids line replacement, reduces procedure risk, and helps preserve access sitesespecially important for dialysis and oncology patients. This clinical logic is also why companies publicly frame catheter clearance as an attractive commercial segment when they talk about bringing urokinase products back to market. A second demand segment is catheter-directed thrombolysis (CDT) for limb-threatening peripheral arterial occlusion or extensive venous thrombosis, where drug is infused locally through a catheter rather than given as a full systemic infusion. Product information for urokinase in Europe explicitly describes acute peripheral arterial occlusions and notes that catheter-directed local lysis is the preferred method of administration for that scenario. More recent reviews also describe CDT as an effective endovascular method for thrombotic peripheral artery occlusions, while emphasizing the need for careful monitoring because bleeding and other complications are real. This creates a steady, procedure-linked demand for urokinase (and competing thrombolytics) in hospitals that perform vascular interventions. The market driver here is not only disease incidence; it is the expansion of interventional capability, better imaging, and more hospitals building vascular teams that can do minimally invasive clot removal rather than open surgery in selected patients. At the same time, a major market trend is that urokinase is not the only clot-buster, and in some very large indications it has been replaced by other approaches. In acute ischemic stroke, for example, many regions use alteplase or tenecteplase, and mechanical thrombectomy has grown for large-vessel occlusions. In myocardial infarction, primary PCI has replaced thrombolysis in many systems where rapid catheterization is available. These shifts matter because they move thrombolytic use toward more specialized niches. In catheter clearance specifically, alteplase has strong clinical adoption in many settings, and reviews discuss its clearance rates and how other agents compare. So, one trend in the urokinase market is narrower but deeper: fewer broad, mass-market indications, but ongoing need in hospital procedures and device-related clots where protocols and economics favor certain agents. Infinity Market Research newest research report, the Urokinase Powder Industry Forecast looks at past sales and reviews total world Urokinase Powder sales in 2025, providing a comprehensive analysis by region and market sector of projected Urokinase Powder sales for 2026 through 2032. With Urokinase Powder sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urokinase Powder industry. This Insight Report provides a comprehensive analysis of the global Urokinase Powder landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urokinase Powder portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Urokinase Powder market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urokinase Powder and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urokinase Powder. This report presents a comprehensive overview, market shares, and growth opportunities of Urokinase Powder market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Animal Urokinase Powder &nbsp;&nbsp;&nbsp; Human Urokinase Powder &nbsp;&nbsp;&nbsp; Segmentation by Clinical Use: &nbsp;&nbsp;&nbsp; Pulmonary Embolism Thrombolysis &nbsp;&nbsp;&nbsp; Deep Vein Thrombosis &nbsp;&nbsp;&nbsp; Peripheral Arterial Occlusion Thrombolysis &nbsp;&nbsp;&nbsp; Catheter / Cannula Occlusion Clearance &nbsp;&nbsp;&nbsp; Others &nbsp;&nbsp;&nbsp; Segmentation by Administration Approach: &nbsp;&nbsp;&nbsp; Systemic Infusion &nbsp;&nbsp;&nbsp; Catheter-directed Thrombolysis (CDT) &nbsp;&nbsp;&nbsp; Intracatheter Dwell / Lock Technique &nbsp;&nbsp;&nbsp; Segmentation by Purity: &nbsp;&nbsp;&nbsp; Standard Clinical Grade &nbsp;&nbsp;&nbsp; High-purity / Low-impurity Grade &nbsp;&nbsp;&nbsp; Low Endotoxin / Low Bioburden Specifications Segmentation by Application: &nbsp;&nbsp;&nbsp; Vascular Disease &nbsp;&nbsp;&nbsp; Vascular Surgery &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Techpool &nbsp;&nbsp;&nbsp; Syner-Med &nbsp;&nbsp;&nbsp; Microbic Biosystems &nbsp;&nbsp;&nbsp; Wanhua Biochem &nbsp;&nbsp;&nbsp; LIVZON &nbsp;&nbsp;&nbsp; Jiangxi Haoran Bio-Pharma &nbsp;&nbsp;&nbsp; Jiangsu Aidea Pharmaceutical &nbsp;&nbsp;&nbsp; Wuhan Humanwell Pharma &nbsp;&nbsp;&nbsp; Tianjin Biochem Pharma Key Questions Addressed in this Report What is the 10-year outlook for the global Urokinase Powder market? What factors are driving Urokinase Powder market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Urokinase Powder market opportunities vary by end market size? How does Urokinase Powder break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Urokinase Powder Annual Sales 2021-2032 &nbsp;2.1.2 World Current & Future Analysis for Urokinase Powder by Geographic Region, 2021, 2025 & 2032 &nbsp;2.1.3 World Current & Future Analysis for Urokinase Powder by Country/Region, 2021, 2025 & 2032 &nbsp;2.2 Urokinase Powder Segment by Type &nbsp;2.2.1 Animal Urokinase Powder &nbsp;2.2.2 Human Urokinase Powder &nbsp;2.2.3 Urokinase Powder Sales by Type &nbsp;2.2.3.1 Global Urokinase Powder Sales Market Share by Type (2021-2026) &nbsp;2.2.3.2 Global Urokinase Powder Revenue and Market Share by Type (2021-2026) &nbsp;2.2.3.3 Global Urokinase Powder Sale Price by Type (2021-2026) &nbsp;2.3 Urokinase Powder Segment by Clinical Use &nbsp;2.3.1 Pulmonary Embolism Thrombolysis &nbsp;2.3.2 Deep Vein Thrombosis &nbsp;2.3.3 Peripheral Arterial Occlusion Thrombolysis &nbsp;2.3.4 Catheter / Cannula Occlusion Clearance &nbsp;2.3.5 Others &nbsp;2.3.6 Urokinase Powder Sales by Clinical Use &nbsp;2.3.6.1 Global Urokinase Powder Sales Market Share by Clinical Use (2021-2026) &nbsp;2.3.6.2 Global Urokinase Powder Revenue and Market Share by Clinical Use (2021-2026) &nbsp;2.3.6.3 Global Urokinase Powder Sale Price by Clinical Use (2021-2026) &nbsp;2.4 Urokinase Powder Segment by Administration Approach &nbsp;2.4.1 Systemic Infusion &nbsp;2.4.2 Catheter-directed Thrombolysis (CDT) &nbsp;2.4.3 Intracatheter Dwell / Lock Technique &nbsp;2.4.4 Urokinase Powder Sales by Administration Approach &nbsp;2.4.4.1 Global Urokinase Powder Sales Market Share by Administration Approach (2021-2026) &nbsp;2.4.4.2 Global Urokinase Powder Revenue and Market Share by Administration Approach (2021-2026) &nbsp;2.4.4.3 Global Urokinase Powder Sale Price by Administration Approach (2021-2026) &nbsp;2.5 Urokinase Powder Segment by Purity &nbsp;2.5.1 Standard Clinical Grade &nbsp;2.5.2 High-purity / Low-impurity Grade &nbsp;2.5.3 Low Endotoxin / Low Bioburden Specifications &nbsp;2.5.4 Urokinase Powder Sales by Purity &nbsp;2.5.4.1 Global Urokinase Powder Sales Market Share by Purity (2021-2026) &nbsp;2.5.4.2 Global Urokinase Powder Revenue and Market Share by Purity (2021-2026) &nbsp;2.5.4.3 Global Urokinase Powder Sale Price by Purity (2021-2026) &nbsp;2.6 Urokinase Powder Segment by Application &nbsp;2.6.1 Vascular Disease &nbsp;2.6.2 Vascular Surgery &nbsp;2.6.3 Others &nbsp;2.6.4 Urokinase Powder Sales by Application &nbsp;2.6.4.1 Global Urokinase Powder Sale Market Share by Application (2021-2026) &nbsp;2.6.4.2 Global Urokinase Powder Revenue and Market Share by Application (2021-2026) &nbsp;2.6.4.3 Global Urokinase Powder Sale Price by Application (2021-2026) 3 Global by Company &nbsp;3.1 Global Urokinase Powder Breakdown Data by Company &nbsp;3.1.1 Global Urokinase Powder Annual Sales by Company (2021-2026) &nbsp;3.1.2 Global Urokinase Powder Sales Market Share by Company (2021-2026) &nbsp;3.2 Global Urokinase Powder Annual Revenue by Company (2021-2026) &nbsp;3.2.1 Global Urokinase Powder Revenue by Company (2021-2026) &nbsp;3.2.2 Global Urokinase Powder Revenue Market Share by Company (2021-2026) &nbsp;3.3 Global Urokinase Powder Sale Price by Company &nbsp;3.4 Key Manufacturers Urokinase Powder Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Urokinase Powder Product Location Distribution &nbsp;3.4.2 Players Urokinase Powder Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Urokinase Powder by Geographic Region &nbsp;4.1 World Historic Urokinase Powder Market Size by Geographic Region (2021-2026) &nbsp;4.1.1 Global Urokinase Powder Annual Sales by Geographic Region (2021-2026) &nbsp;4.1.2 Global Urokinase Powder Annual Revenue by Geographic Region (2021-2026) &nbsp;4.2 World Historic Urokinase Powder Market Size by Country/Region (2021-2026) &nbsp;4.2.1 Global Urokinase Powder Annual Sales by Country/Region (2021-2026) &nbsp;4.2.2 Global Urokinase Powder Annual Revenue by Country/Region (2021-2026) &nbsp;4.3 Americas Urokinase Powder Sales Growth &nbsp;4.4 APAC Urokinase Powder Sales Growth &nbsp;4.5 Europe Urokinase Powder Sales Growth &nbsp;4.6 Middle East & Africa Urokinase Powder Sales Growth 5 Americas &nbsp;5.1 Americas Urokinase Powder Sales by Country &nbsp;5.1.1 Americas Urokinase Powder Sales by Country (2021-2026) &nbsp;5.1.2 Americas Urokinase Powder Revenue by Country (2021-2026) &nbsp;5.2 Americas Urokinase Powder Sales by Type (2021-2026) &nbsp;5.3 Americas Urokinase Powder Sales by Application (2021-2026) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Urokinase Powder Sales by Region &nbsp;6.1.1 APAC Urokinase Powder Sales by Region (2021-2026) &nbsp;6.1.2 APAC Urokinase Powder Revenue by Region (2021-2026) &nbsp;6.2 APAC Urokinase Powder Sales by Type (2021-2026) &nbsp;6.3 APAC Urokinase Powder Sales by Application (2021-2026) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Urokinase Powder by Country &nbsp;7.1.1 Europe Urokinase Powder Sales by Country (2021-2026) &nbsp;7.1.2 Europe Urokinase Powder Revenue by Country (2021-2026) &nbsp;7.2 Europe Urokinase Powder Sales by Type (2021-2026) &nbsp;7.3 Europe Urokinase Powder Sales by Application (2021-2026) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Urokinase Powder by Country &nbsp;8.1.1 Middle East & Africa Urokinase Powder Sales by Country (2021-2026) &nbsp;8.1.2 Middle East & Africa Urokinase Powder Revenue by Country (2021-2026) &nbsp;8.2 Middle East & Africa Urokinase Powder Sales by Type (2021-2026) &nbsp;8.3 Middle East & Africa Urokinase Powder Sales by Application (2021-2026) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Urokinase Powder &nbsp;10.3 Manufacturing Process Analysis of Urokinase Powder &nbsp;10.4 Industry Chain Structure of Urokinase Powder 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Urokinase Powder Distributors &nbsp;11.3 Urokinase Powder Customer 12 World Forecast Review for Urokinase Powder by Geographic Region &nbsp;12.1 Global Urokinase Powder Market Size Forecast by Region &nbsp;12.1.1 Global Urokinase Powder Forecast by Region (2027-2032) &nbsp;12.1.2 Global Urokinase Powder Annual Revenue Forecast by Region (2027-2032) &nbsp;12.2 Americas Forecast by Country (2027-2032) &nbsp;12.3 APAC Forecast by Region (2027-2032) &nbsp;12.4 Europe Forecast by Country (2027-2032) &nbsp;12.5 Middle East & Africa Forecast by Country (2027-2032) &nbsp;12.6 Global Urokinase Powder Forecast by Type (2027-2032) &nbsp;12.7 Global Urokinase Powder Forecast by Application (2027-2032) 13 Key Players Analysis &nbsp;13.1 Techpool &nbsp;13.1.1 Techpool Company Information &nbsp;13.1.2 Techpool Urokinase Powder Product Portfolios and Specifications &nbsp;13.1.3 Techpool Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.1.4 Techpool Main Business Overview &nbsp;13.1.5 Techpool Latest Developments &nbsp;13.2 Syner-Med &nbsp;13.2.1 Syner-Med Company Information &nbsp;13.2.2 Syner-Med Urokinase Powder Product Portfolios and Specifications &nbsp;13.2.3 Syner-Med Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.2.4 Syner-Med Main Business Overview &nbsp;13.2.5 Syner-Med Latest Developments &nbsp;13.3 Microbic Biosystems &nbsp;13.3.1 Microbic Biosystems Company Information &nbsp;13.3.2 Microbic Biosystems Urokinase Powder Product Portfolios and Specifications &nbsp;13.3.3 Microbic Biosystems Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.3.4 Microbic Biosystems Main Business Overview &nbsp;13.3.5 Microbic Biosystems Latest Developments &nbsp;13.4 Wanhua Biochem &nbsp;13.4.1 Wanhua Biochem Company Information &nbsp;13.4.2 Wanhua Biochem Urokinase Powder Product Portfolios and Specifications &nbsp;13.4.3 Wanhua Biochem Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.4.4 Wanhua Biochem Main Business Overview &nbsp;13.4.5 Wanhua Biochem Latest Developments &nbsp;13.5 LIVZON &nbsp;13.5.1 LIVZON Company Information &nbsp;13.5.2 LIVZON Urokinase Powder Product Portfolios and Specifications &nbsp;13.5.3 LIVZON Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.5.4 LIVZON Main Business Overview &nbsp;13.5.5 LIVZON Latest Developments &nbsp;13.6 Jiangxi Haoran Bio-Pharma &nbsp;13.6.1 Jiangxi Haoran Bio-Pharma Company Information &nbsp;13.6.2 Jiangxi Haoran Bio-Pharma Urokinase Powder Product Portfolios and Specifications &nbsp;13.6.3 Jiangxi Haoran Bio-Pharma Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.6.4 Jiangxi Haoran Bio-Pharma Main Business Overview &nbsp;13.6.5 Jiangxi Haoran Bio-Pharma Latest Developments &nbsp;13.7 Jiangsu Aidea Pharmaceutical &nbsp;13.7.1 Jiangsu Aidea Pharmaceutical Company Information &nbsp;13.7.2 Jiangsu Aidea Pharmaceutical Urokinase Powder Product Portfolios and Specifications &nbsp;13.7.3 Jiangsu Aidea Pharmaceutical Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.7.4 Jiangsu Aidea Pharmaceutical Main Business Overview &nbsp;13.7.5 Jiangsu Aidea Pharmaceutical Latest Developments &nbsp;13.8 Wuhan Humanwell Pharma &nbsp;13.8.1 Wuhan Humanwell Pharma Company Information &nbsp;13.8.2 Wuhan Humanwell Pharma Urokinase Powder Product Portfolios and Specifications &nbsp;13.8.3 Wuhan Humanwell Pharma Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.8.4 Wuhan Humanwell Pharma Main Business Overview &nbsp;13.8.5 Wuhan Humanwell Pharma Latest Developments &nbsp;13.9 Tianjin Biochem Pharma &nbsp;13.9.1 Tianjin Biochem Pharma Company Information &nbsp;13.9.2 Tianjin Biochem Pharma Urokinase Powder Product Portfolios and Specifications &nbsp;13.9.3 Tianjin Biochem Pharma Urokinase Powder Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.9.4 Tianjin Biochem Pharma Main Business Overview &nbsp;13.9.5 Tianjin Biochem Pharma Latest Developments 14 Research Findings and Conclusion

Report	Global Urokinase Powder Market Growth 2026-2032
Selected License	Multi ID: ILR1364

Buyer Information

Order Summary